<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774019</url>
  </required_header>
  <id_info>
    <org_study_id>90914721</org_study_id>
    <secondary_id>E7059</secondary_id>
    <nct_id>NCT01774019</nct_id>
  </id_info>
  <brief_title>Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer</brief_title>
  <official_title>Randomized Multi-Center Study Comparing No Drainage to Preoperative Biliary Drainage Using Metal Stents in Patients With Resectable Pancreatic or Periampullary Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that preoperative biliary drainage using&#xD;
      self-expanding metal stents (SEMS) does not negatively impact overall surgical outcomes in&#xD;
      patients undergoing pancreaticoduodenectomy for treatment of pancreatic or periampullary&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 20, 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of serious pre-operative, operative and post-operative adverse events to 120 days post randomization or to 30 days post surgery, whichever comes last</measure>
    <time_frame>120 days</time_frame>
    <description>Count of Serious Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Procedure - 120 days</time_frame>
    <description>Adverse events will be assessed in terms of rate, severity, seriousness, relatedness to stent or endoscopic or surgical procedure, impact on time of surgery, length of hospitalization and ICU stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to surgery</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Days until subject undergoes surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Curative Intent Surgery details pertaining to intraoperative assessment of resectability, surgical resection and reconstruction techniques.</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Details related to Curative Intent Surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of intraoperative blood loss and number of blood transfusions, duration of surgery</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Intraoperative blood loss in ml, count of transfusions and time from start to finish of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biliary obstructive symptoms assessment</measure>
    <time_frame>Baseline - 120 days</time_frame>
    <description>Record of symptoms associated with biliary obstruction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of liver function test (LFT) levels as relative to baseline</measure>
    <time_frame>Week 2 - 120 days</time_frame>
    <description>Laboratory tests for liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent placement success</measure>
    <time_frame>Procedure</time_frame>
    <description>Stent placement success: ability to deploy the stent in satisfactory position across the stricture (For patients who are randomized to biliary drainage with a metal stent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent removal success</measure>
    <time_frame>At time of surgery or prior to surgery if re-intervention is needed.</time_frame>
    <description>Stent removal success: successful SEMS removal, either en bloc at time of surgery or endoscopically prior to surgery without stent removal related SAEs (For patients who are randomized to biliary drainage with a metal stent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number, type, reason, and timing of biliary re-interventions</measure>
    <time_frame>Baseline - 120 days</time_frame>
    <description>Count and timing of biliary re-interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital and ICU admissions</measure>
    <time_frame>Procedure - 120 days</time_frame>
    <description>Count of admissions to hospital and ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital and ICU admissions</measure>
    <time_frame>Procedure - 120 days</time_frame>
    <description>Length of stay in hospital and ICU</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">287</enrollment>
  <condition>Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>WallFlex™ Biliary RX Fully Covered/Uncovered Stent System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive a fully covered or uncovered study SEMS (self-expanding metal stent)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>None (No Pre-Operative Biliary Drainage)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this group will not receive pre-operative biliary drainage with a study SEMS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WallFlex™ Biliary RX Fully Covered/Uncovered Stent System</intervention_name>
    <arm_group_label>WallFlex™ Biliary RX Fully Covered/Uncovered Stent System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Willing and able to comply with the study procedures and provide written informed&#xD;
             consent to participate in the study&#xD;
&#xD;
          -  Diagnosis of probable pancreatic cancer, distal common bile duct (CBD)&#xD;
             cholangiocarcinoma and other periampullary cancers (histology not required)&#xD;
&#xD;
          -  Biliary obstructive symptoms or signs&#xD;
&#xD;
          -  Bilirubin level at/above 100 umol per liter (5.8 mg/dL)&#xD;
&#xD;
          -  Distal biliary obstruction consistent with pancreatic cancer, distal CBD&#xD;
             cholangiocarcinoma or other periampullary malignancy&#xD;
&#xD;
          -  Location of distal biliary obstruction is such that it would allow the proximal end of&#xD;
             a stent to be positioned at least 2cm from the hilum&#xD;
&#xD;
          -  Patients deemed as resectable by pancreatic protocol CT or MRI&#xD;
&#xD;
          -  Surgical candidate per pancreatobiliary surgeon after multi-disciplinary discussion&#xD;
&#xD;
          -  Surgery intent within 4 weeks&#xD;
&#xD;
          -  Endoscopic and surgical treatment to be provided by same team&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Biliary strictures caused by confirmed benign tumors&#xD;
&#xD;
          -  Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD&#xD;
             cholangiocarcinoma and other periampullary cancers&#xD;
&#xD;
          -  Surgically altered biliary tract anatomy, not including prior cholecystectomy&#xD;
&#xD;
          -  Neoadjuvant chemotherapy for current malignancy&#xD;
&#xD;
          -  Palliative indication due to reasons other than surgical candidate status&#xD;
&#xD;
          -  Previous biliary drainage by ERCP/PTC&#xD;
&#xD;
          -  Patients for whom endoscopic techniques are contraindicated&#xD;
&#xD;
          -  Participation in another investigational trial within 90 days&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Costamagna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Universitario Agostino Gemelli</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Standford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Diseases Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital, the Chinese University of Hong Kong</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asian Institute of Gastroenterology</name>
      <address>
        <city>Hyderabad</city>
        <zip>500 082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>China</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 2, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic</keyword>
  <keyword>Periampullary Cancer</keyword>
  <keyword>Preoperative Biliary Drainage</keyword>
  <keyword>Resectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

